• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Point of Care Diagnostics Testing Market Trends

    ID: MRFR/HC/9161-HCR
    120 Pages
    Rahul Gotadki
    October 2025

    Point of Care Diagnostics Testing Market By Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing), By End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing), By Mode of Purchase...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Point of Care Diagnostics Testing Market Infographic
    Purchase Options

    Market Trends

    Key Emerging Trends in the Point of Care Diagnostics Testing Market

    Changes have occurred in Point of Care Diagnostics/Testing (POCT) due to technological advancements that have necessitated rapid and accessible diagnostic solutions to changing healthcare needs. One such trend is the expansion in testing capabilities at the point of care, enabling quick decentralized diagnostics results. The use of modern technologies is one factor behind market trends in POCT. Smaller sizes of machinery-driven integration with digital platforms count among significant developments made so far toward improving nature diagnostics products. Portable analyzers, handheld devices, and smartphone-based applications are now common, providing quick, accurate tests for different medical conditions. Apart from facilitating testing efficiencies, these innovations provide healthcare services in varied settings. Such a trend also exists in POCT, where diagnosing beyond infectious diseases has been extended to chronic conditions. These include diabetes, cardiovascular diseases, and cancer markers; thus, there are POC devices that offer rapid diagnosis for them, too. The adoption of decentralized diagnostic networks is another emerging pattern within this marketplace. In this regard, POCT systems become part of bigger diagnostic networks that facilitate data sharing without interruptions or breaks, hence ensuring continuous result reporting. This trend correspondingly aligns with the wider acceptance of digital health solutions, thereby creating a more interconnected data-driven procedure that deals with patients. Decentralized networks promote cooperation among healthcare providers and improve patient management by means of real-time information sharing. POCT is driven by affordability and access, which shapes its market dynamics. Since cost-effective diagnostics are in demand, affordable POCT devices have been developed to suit various healthcare settings, including resource-poor areas. In efforts to make healthcare more inclusive, governments, organizations, and manufacturers focus on producing affordable POCT technologies aimed at increasing the availability of diagnostics worldwide in different locations. Furthermore, the COVID-19 pandemic has had an impact on POCT market trends. The need for decentralized testing solutions was underscored during the pandemic when there was a great demand for quick and widespread testing. Rapid antigen tests, as well as molecular diagnostics, were used in mass testing efforts, contact tracing, and containment of the virus, hence playing a crucial role. Prompt diagnosis was made possible through POCT devices like rapid antigen tests along with other molecular diagnostics, which formed an integral part of the national COVID-19 response, including large-scale contact tracing initiatives that helped curb further spread. The experience taught us how POC technologies are adaptive; therefore, they provide enough resilience even during moments of public health crises.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the CAGR for Point of Care Diagnostics Testing Market?

    The Point of Care Diagnostics/Testing Market can expand at 9.58% CAGR by 2035.

    Who are key players of the Point of Care Diagnostics Testing Market?

    Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson & Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US) Are the key players of market

    What is the valuation of the Point of Care Diagnostics Testing Market?

    By 2035, the Point of Care Diagnostics/Testing Market value can exceed USD 157.87 Billion.

    What is the Point of Care Diagnostics Testing Market driver?

    Increasing demand for COVID-19 POC test kits is driving the Point of Care Diagnostics/Testing Market.

    What is the Point of Care Diagnostics Testing Market restrain?

    Increases the potential of rapid medical diagnosis restrain the Point of Care Diagnostics/Testing Market.

    Market Summary

    As per MRFR analysis, the Point of Care Diagnostics Testing Market was estimated at 57.71 USD Billion in 2024. The Point of Care Diagnostics Testing industry is projected to grow from 63.24 USD Billion in 2025 to 157.87 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.58 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Point of Care Diagnostics Testing Market is experiencing robust growth driven by technological advancements and a shift towards decentralized healthcare.

    • Technological advancements are enhancing the accuracy and speed of point of care diagnostics, particularly in glucose monitoring.
    • The demand for decentralized testing is rising, especially in the Asia-Pacific region, as patients seek more accessible healthcare solutions.
    • Personalized medicine is gaining traction, influencing the development of tailored diagnostic tests in hospitals and clinics.
    • Key market drivers include technological innovations in point of care diagnostics and the rising prevalence of chronic diseases, which are shaping market dynamics.

    Market Size & Forecast

    2024 Market Size 57.71 (USD Billion)
    2035 Market Size 157.87 (USD Billion)
    CAGR (2025 - 2035) 9.58%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Danaher Corporation (US), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Cepheid (US), Quidel Corporation (US), Hologic, Inc. (US)</p>

    Market Trends

    The Point of Care Diagnostics Testing Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing demand for immediate diagnostic solutions. This market encompasses a wide array of testing devices and methodologies that facilitate quick results, often at the site of patient care. The growing emphasis on personalized medicine and the need for efficient healthcare delivery systems are driving innovations in this sector. Furthermore, the integration of digital health technologies, such as telemedicine and mobile health applications, appears to enhance the accessibility and efficiency of point-of-care testing, thereby expanding its reach across various healthcare settings. In addition, the Point of Care Diagnostics Testing Market is likely to benefit from the rising prevalence of chronic diseases and the aging population, which necessitate regular monitoring and timely interventions. The shift towards decentralized healthcare models, where testing occurs outside traditional laboratory environments, suggests a significant change in how healthcare services are delivered. As stakeholders continue to invest in research and development, the market is poised for sustained growth, with new products and solutions emerging to meet the evolving needs of patients and healthcare providers alike.

    Technological Advancements

    The Point of Care Diagnostics Testing Market is witnessing a surge in technological innovations, particularly in the development of portable and user-friendly devices. These advancements facilitate rapid testing and improve accuracy, thereby enhancing patient outcomes. The integration of artificial intelligence and machine learning into diagnostic tools is also becoming more prevalent, allowing for more precise interpretations of results.

    Increased Demand for Decentralized Testing

    There is a notable shift towards decentralized testing solutions within the Point of Care Diagnostics Testing Market. This trend is driven by the need for immediate results and the convenience of testing in non-traditional settings, such as homes and remote locations. As healthcare systems adapt to this model, the market is likely to expand, catering to a broader range of patient needs.

    Focus on Personalized Medicine

    The emphasis on personalized medicine is reshaping the Point of Care Diagnostics Testing Market. Tailoring diagnostic tests to individual patient profiles enhances treatment efficacy and fosters better health management. This trend indicates a growing recognition of the importance of individualized care, which is expected to influence product development and market strategies.

    <p>The Global Point of Care Diagnostics Testing Market is poised for substantial growth, driven by advancements in technology and an increasing demand for rapid diagnostic solutions in various healthcare settings.</p>

    U.S. Food and Drug Administration (FDA)

    Point of Care Diagnostics Testing Market Market Drivers

    Rising Prevalence of Chronic Diseases

    The increasing prevalence of chronic diseases is a significant driver for the Point of Care Diagnostics Testing Market. Conditions such as diabetes, cardiovascular diseases, and respiratory disorders necessitate regular monitoring and timely interventions. As the global population ages, the demand for rapid diagnostic solutions that can be administered at home or in outpatient settings is likely to rise. Market data suggests that the incidence of diabetes alone is expected to reach 700 million cases by 2045, underscoring the urgent need for effective point of care testing solutions. This trend not only emphasizes the importance of early detection but also highlights the potential for point of care diagnostics to improve patient outcomes through timely treatment. Consequently, healthcare providers are increasingly adopting these technologies to enhance patient management and reduce healthcare costs.

    Shift Towards Decentralized Healthcare

    The Point of Care Diagnostics Testing Market is witnessing a notable shift towards decentralized healthcare models. This transformation is driven by the need for accessible and efficient healthcare services, particularly in remote or underserved areas. Decentralized testing allows for immediate results, reducing the need for patients to travel to centralized laboratories. Recent statistics indicate that the market for decentralized diagnostics is expected to grow at a compound annual growth rate of 10% over the next five years. This growth is fueled by the increasing adoption of telemedicine and home healthcare services, which are becoming integral to modern healthcare delivery. As a result, point of care diagnostics are positioned to play a crucial role in facilitating timely medical interventions and improving overall healthcare accessibility.

    Increased Focus on Preventive Healthcare

    The Point of Care Diagnostics Testing Market is significantly influenced by the growing emphasis on preventive healthcare. As healthcare systems worldwide shift from reactive to proactive approaches, the demand for early detection and monitoring tools is escalating. Preventive diagnostics enable healthcare providers to identify potential health issues before they escalate, thereby reducing the burden on healthcare systems. Market analysis indicates that the preventive healthcare market is projected to reach USD 200 billion by 2027, with point of care testing being a vital component. This trend is further supported by public health initiatives aimed at promoting regular health screenings and awareness campaigns. Consequently, the integration of point of care diagnostics into routine healthcare practices is likely to enhance patient engagement and foster a culture of preventive care.

    Regulatory Support and Reimbursement Policies

    The Point of Care Diagnostics Testing Market is benefiting from favorable regulatory support and evolving reimbursement policies. Governments and health authorities are increasingly recognizing the value of point of care testing in improving healthcare outcomes and reducing costs. Recent policy changes have streamlined the approval processes for new diagnostic devices, facilitating quicker market entry. Additionally, reimbursement frameworks are adapting to include point of care tests, making them more financially viable for healthcare providers. This regulatory environment is expected to encourage innovation and investment in point of care diagnostics, as evidenced by the projected growth of the market, which is anticipated to reach USD 60 billion by 2028. Such supportive measures are likely to enhance the adoption of point of care testing across various healthcare settings, ultimately benefiting patients and providers alike.

    Technological Innovations in Point of Care Diagnostics

    The Point of Care Diagnostics Testing Market is experiencing a surge in technological innovations that enhance testing accuracy and speed. Advancements in microfluidics, biosensors, and portable devices are transforming traditional diagnostic methods. For instance, the integration of artificial intelligence in diagnostic tools is streamlining data analysis, leading to quicker decision-making. According to recent data, the market for point of care testing devices is projected to reach USD 50 billion by 2026, driven by these technological advancements. Furthermore, the development of multiplex testing capabilities allows for simultaneous detection of multiple pathogens, which is particularly beneficial in managing infectious diseases. This trend indicates a shift towards more efficient and user-friendly diagnostic solutions, making them increasingly accessible in various healthcare settings.

    Market Segment Insights

    By Product: Glucose Monitoring (Largest) vs. Infectious Disease Testing (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, Glucose Monitoring stands out as the largest segment, capturing a substantial share of the market with its widespread use in managing diabetes. Other significant segments include Cardiometabolic Monitoring and Coagulation Monitoring; however, their market shares are comparatively smaller. On the other hand, Infectious Disease Testing is emerging rapidly, driven by recent global health challenges, highlighting the demand for quick and reliable testing methods among healthcare providers and patients alike.</p>

    <p>Glucose Monitoring (Dominant) vs. Infectious Disease Testing (Emerging)</p>

    <p>Glucose Monitoring is a well-established segment in the Point of Care Diagnostics Testing Market, primarily utilized by individuals with diabetes for managing blood sugar levels. Its dominance is fueled by technological advancements, such as continuous glucose monitoring systems that provide real-time data, enhancing patient compliance and outcomes. Conversely, Infectious Disease Testing is a rapidly emerging segment that has gained momentum, especially due to the urgent need for rapid testing solutions following global health crises. This segment encompasses innovations in testing methodologies and increased accessibility, focusing on delivering swift and accurate results for a wider array of infectious diseases, thus positioning it as a crucial player in the market.</p>

    By End User: Hospitals & Clinics (Largest) vs. Homecare/Self Testing (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, hospitals and clinics stand out as the largest segment, owing to their significant patient footfall and increasing demand for quick diagnostic solutions. Diagnostic centers follow closely, providing specialized services that cater to diverse testing needs. Meanwhile, homecare/self-testing is gaining traction among consumers who prefer convenience and immediate results, particularly in the wake of the growing emphasis on remote healthcare.</p>

    <p>End User: Hospitals & Clinics (Dominant) vs. Homecare/Self Testing (Emerging)</p>

    <p>Hospitals and clinics dominate the Point of Care Diagnostics Testing Market due to their established infrastructure and ability to manage high patient volumes efficiently. They frequently utilize advanced diagnostic technologies to facilitate timely decision-making and improve patient outcomes. On the other hand, homecare/self-testing is an emerging segment characterized by its accessibility and user-friendly nature, appealing primarily to health-conscious individuals seeking to monitor their conditions privately. This segment is witnessing rapid growth, driven by innovations in testing kits and the rising demand for at-home health solutions, ultimately reshaping traditional healthcare delivery.</p>

    By Mode of Purchase: OTC Testing Products (Largest) vs. Prescription-based Testing Products (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, the distribution of market share between OTC testing products and prescription-based testing products reveals a clear dominance of OTC products. OTC testing products cater to the growing demand for self-testing and at-home diagnostics, which is increasingly preferred by consumers seeking convenience and accessibility. Prescription-based testing products, while smaller in market share, are rapidly gaining traction due to their specific applications and trusted results, favored by healthcare providers for accuracy and reliability. The growth trends in this segment are indicative of evolving consumer preferences and advancements in technology. The increase in health awareness and the shift towards personalized healthcare solutions drive the demand for OTC testing products, which are positioned for immediate use without needing a healthcare provider. Conversely, prescription-based testing products are experiencing a surge in demand as healthcare systems emphasize more accurate diagnostics and a move towards comprehensive patient management, signaling an emerging trend that is likely to expand in the coming years.</p>

    <p>Mode of Purchase: OTC Testing Products (Dominant) vs. Prescription-based Testing Products (Emerging)</p>

    <p>OTC testing products have established themselves as the dominant force in the Point of Care Diagnostics Testing Market, thanks to their ease of use and accessibility. These products empower consumers to take charge of their health, offering the advantage of timely testing without the need for medical appointments. Their popularity is reinforced by a wide range of applications, including disease screening and health monitoring. In contrast, prescription-based testing products are emerging rapidly, showcasing a different set of characteristics. They are characterized by their accuracy and are often used in clinical settings where precise diagnostics are crucial. These products are supported by healthcare professionals and are gaining acceptance among patients who trust their reliability. Together, these two segments highlight a comprehensive approach to diagnostics, catering to diverse consumer needs.</p>

    By Platform: Immunoassays (Largest) vs. Molecular Diagnostics (Fastest-Growing)

    <p>In the Point of Care Diagnostics Testing Market, the distribution of market share among the key platforms reveals that Immunoassays hold the largest portion of the market. This is largely due to their established use in various diagnostics applications, making them a preferred choice for healthcare providers. In contrast, Molecular Diagnostics, while smaller in market share, are rapidly gaining traction owing to advancements in technology and increasing demand for precision testing. Dipsticks, although recognized, remain at the periphery of this growth in terms of overall market share compared to the other two platforms.</p>

    <p>Immunoassays (Dominant) vs. Dipsticks (Emerging)</p>

    <p>Immunoassays dominate the Point of Care Diagnostics Testing Market due to their reliability, ease of use, and versatility across various medical conditions. They are highly sought after for their capacity to provide rapid and accurate results, which is paramount in urgent care settings. Dipsticks, on the other hand, represent an emerging platform that, while historically used for basic diagnostics like glucose monitoring, are innovating with new applications. They offer low-cost, portable solutions but lack the comprehensive capabilities of Immunoassays, positioning them as a supplementary rather than primary choice in the diagnostics landscape.</p>

    Get more detailed insights about Point of Care Diagnostics Testing Market Research Report - Global Forecast till 2035

    Regional Insights

    North America : Leading Innovation and Adoption

    North America is the largest market for Point of Care Diagnostics Testing, holding approximately 45% of the global market share. The region's growth is driven by increasing demand for rapid diagnostic tests, technological advancements, and supportive regulatory frameworks. The COVID-19 pandemic has further accelerated the adoption of point-of-care testing, leading to significant investments in healthcare infrastructure and innovation. The United States is the primary contributor to this market, with key players like Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. The presence of advanced healthcare facilities and a focus on personalized medicine further bolster the market's growth in this region.

    Europe : Regulatory Support and Growth

    Europe is the second-largest market for Point of Care Diagnostics Testing, accounting for approximately 30% of the global market share. The region benefits from stringent regulatory standards that ensure the quality and reliability of diagnostic tests. Increasing prevalence of chronic diseases and a growing emphasis on preventive healthcare are key drivers of market growth. The European Union's initiatives to enhance healthcare accessibility also play a significant role in shaping the market landscape. Leading countries in this region include Germany, France, and the UK, where companies like Siemens Healthineers and Roche Diagnostics are prominent. The competitive environment is marked by innovation and collaboration among various stakeholders, including healthcare providers and technology firms. The presence of robust healthcare systems and a focus on research and development further enhance the market's potential.

    Asia-Pacific : Rapid Growth and Expansion

    Asia-Pacific is witnessing rapid growth in the Point of Care Diagnostics Testing market, holding approximately 20% of the global market share. The region's growth is fueled by rising healthcare expenditures, increasing awareness of early disease detection, and a growing aging population. Additionally, government initiatives aimed at improving healthcare infrastructure and access to diagnostic services are significant catalysts for market expansion. Countries like China, India, and Japan are leading the charge, with a mix of local and international players such as Danaher Corporation and Becton Dickinson making significant inroads. The competitive landscape is evolving, with a focus on affordable and accessible testing solutions. The region's diverse healthcare needs and varying regulatory environments present both challenges and opportunities for market participants.

    Middle East and Africa : Untapped Potential and Growth

    The Middle East and Africa region is gradually emerging in the Point of Care Diagnostics Testing market, holding about 5% of the global market share. The growth is driven by increasing investments in healthcare infrastructure, rising prevalence of infectious diseases, and a growing focus on improving healthcare access. Government initiatives aimed at enhancing diagnostic capabilities are also contributing to market development in this region. Leading countries include South Africa, UAE, and Saudi Arabia, where local and international companies are beginning to establish a foothold. The competitive landscape is characterized by a mix of established players and new entrants, focusing on innovative solutions tailored to local needs. The region's unique challenges, such as varying healthcare standards and economic disparities, present both hurdles and opportunities for growth.

    Key Players and Competitive Insights

    The Point of Care Diagnostics Testing Market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for rapid diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its product portfolio through continuous innovation, particularly in the development of portable diagnostic devices. Meanwhile, Roche Diagnostics (CH) emphasizes strategic partnerships to bolster its capabilities in molecular diagnostics, thereby enhancing its competitive edge. Siemens Healthineers (DE) is actively pursuing digital transformation initiatives, integrating AI and data analytics into its diagnostic solutions, which positions it favorably in a market that increasingly values technological integration.

    The competitive structure of the Point of Care Diagnostics Testing Market appears moderately fragmented, with several key players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing to reduce costs and optimize supply chains. This approach not only enhances operational efficiency but also allows for quicker response times to market demands. The collective influence of these major players shapes the market dynamics, as they continuously innovate and adapt to changing consumer needs and regulatory environments.

    In August 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading telehealth provider to integrate its point-of-care testing solutions into remote healthcare services. This collaboration is significant as it expands Roche's reach into the telehealth sector, allowing for seamless integration of diagnostic testing with virtual consultations. Such a move not only enhances patient access to diagnostics but also positions Roche as a leader in the evolving landscape of integrated healthcare solutions.

    In September 2025, Abbott Laboratories (US) launched a new rapid diagnostic test for infectious diseases, which utilizes advanced molecular technology to deliver results in under 30 minutes. This innovation is crucial as it addresses the growing demand for quick and accurate testing solutions, particularly in outpatient settings. Abbott's focus on rapid diagnostics aligns with current healthcare trends that prioritize speed and efficiency, potentially solidifying its market position.

    In October 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics platform designed to enhance the accuracy and efficiency of point-of-care testing. This platform aims to provide healthcare professionals with real-time insights, thereby improving patient outcomes. The introduction of such technology reflects Siemens' commitment to integrating advanced analytics into its diagnostic offerings, which is likely to resonate well with healthcare providers seeking to enhance their operational capabilities.

    As of October 2025, the competitive trends in the Point of Care Diagnostics Testing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities and market reach. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancement, and supply chain reliability. This transition underscores the importance of agility and responsiveness in a rapidly changing market environment.

    Key Companies in the Point of Care Diagnostics Testing Market market include

    Industry Developments

    • In June 2021,DCN Dx(US) acquired the pointofcare diagnostics development company PortaScience Inc. (US). This acquisition will expand the point of care product portfolio of the company.
    • In April 2021,the Indian Institute of Technology Kharagpur (India), an Indian engineering institute,launched a nucleic acid-based pointof care diagnostic devicefor COVID-19 diagnosis.
    • In April 2021,LumiraDx (US), a next-generation point of care diagnostics testing company,announced its merger with CA Healthcare Acquisition (CAHC) (US)in a deal worth USD 5 billion.
    • In March 2021, MatMaCorp (US) launched MYRTA, a handheld real-time POCPCR device for molecular diagnostics.
    • In March 2020, Abbott(US) launched the fastest available molecular pointofcare test to detect the coronavirus in less than 5 minutes.

    Future Outlook

    Point of Care Diagnostics Testing Market Future Outlook

    <p>The Point of Care Diagnostics Testing Market is projected to grow at a 9.58% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for rapid testing, and rising healthcare expenditures.</p>

    New opportunities lie in:

    • <p>Development of portable diagnostic devices for remote areas</p>
    • <p>Integration of AI for enhanced diagnostic accuracy</p>
    • <p>Expansion of telehealth services incorporating POC testing</p>

    <p>By 2035, the market is expected to be robust, driven by innovation and increased accessibility.</p>

    Market Segmentation

    Point of Care Diagnostics Testing Market Product Outlook

    • Glucose Monitoring
    • Cardiometabolic Monitoring
    • Infectious Disease Testing
    • Coagulation Monitoring
    • Pregnancy & Fertility Testing
    • Hematology Testing
    • Cancer/Tumor Marker Testing
    • Urinalysis Testing
    • Cholesterol
    • Drugs-of-Abuse Testing

    Point of Care Diagnostics Testing Market End User Outlook

    • Hospitals & Clinics
    • Diagnostic Centers
    • Homecare/Self Testing

    Point of Care Diagnostics Testing Market Platform Outlook

    • Immunoassays
    • Molecular Diagnostics
    • Dipsticks

    Point of Care Diagnostics Testing Market Mode of Purchase Outlook

    • OTC Testing Products
    • Prescription-based testing products

    Report Scope

    MARKET SIZE 202457.71(USD Billion)
    MARKET SIZE 202563.24(USD Billion)
    MARKET SIZE 2035157.87(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)9.58% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesIntegration of artificial intelligence enhances accuracy and efficiency in the Point of Care Diagnostics Testing Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the Point of Care Diagnostics Testing Market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the CAGR for Point of Care Diagnostics Testing Market?

    The Point of Care Diagnostics/Testing Market can expand at 9.58% CAGR by 2035.

    Who are key players of the Point of Care Diagnostics Testing Market?

    Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson &amp; Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US) Are the key players of market

    What is the valuation of the Point of Care Diagnostics Testing Market?

    By 2035, the Point of Care Diagnostics/Testing Market value can exceed USD 157.87 Billion.

    What is the Point of Care Diagnostics Testing Market driver?

    Increasing demand for COVID-19 POC test kits is driving the Point of Care Diagnostics/Testing Market.

    What is the Point of Care Diagnostics Testing Market restrain?

    Increases the potential of rapid medical diagnosis restrain the Point of Care Diagnostics/Testing Market.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Product (USD Billion)
      2. | | 4.1.1 Glucose Monitoring
      3. | | 4.1.2 Cardiometabolic Monitoring
      4. | | 4.1.3 Infectious Disease Testing
      5. | | 4.1.4 Coagulation Monitoring
      6. | | 4.1.5 Pregnancy & Fertility Testing
      7. | | 4.1.6 Hematology Testing
      8. | | 4.1.7 Cancer/Tumor Marker Testing
      9. | | 4.1.8 Urinalysis Testing
      10. | | 4.1.9 Cholesterol
      11. | | 4.1.10 Drugs-of-Abuse Testing
      12. | 4.2 Healthcare, BY End User (USD Billion)
      13. | | 4.2.1 Hospitals & Clinics
      14. | | 4.2.2 Diagnostic Centers
      15. | | 4.2.3 Homecare/Self Testing
      16. | 4.3 Healthcare, BY Mode of Purchase (USD Billion)
      17. | | 4.3.1 OTC Testing Products
      18. | | 4.3.2 Prescription-based testing products
      19. | 4.4 Healthcare, BY Platform (USD Billion)
      20. | | 4.4.1 Immunoassays
      21. | | 4.4.2 Molecular Diagnostics
      22. | | 4.4.3 Dipsticks
      23. | 4.5 Healthcare, BY Region (USD Billion)
      24. | | 4.5.1 North America
      25. | | | 4.5.1.1 US
      26. | | | 4.5.1.2 Canada
      27. | | 4.5.2 Europe
      28. | | | 4.5.2.1 Germany
      29. | | | 4.5.2.2 UK
      30. | | | 4.5.2.3 France
      31. | | | 4.5.2.4 Russia
      32. | | | 4.5.2.5 Italy
      33. | | | 4.5.2.6 Spain
      34. | | | 4.5.2.7 Rest of Europe
      35. | | 4.5.3 APAC
      36. | | | 4.5.3.1 China
      37. | | | 4.5.3.2 India
      38. | | | 4.5.3.3 Japan
      39. | | | 4.5.3.4 South Korea
      40. | | | 4.5.3.5 Malaysia
      41. | | | 4.5.3.6 Thailand
      42. | | | 4.5.3.7 Indonesia
      43. | | | 4.5.3.8 Rest of APAC
      44. | | 4.5.4 South America
      45. | | | 4.5.4.1 Brazil
      46. | | | 4.5.4.2 Mexico
      47. | | | 4.5.4.3 Argentina
      48. | | | 4.5.4.4 Rest of South America
      49. | | 4.5.5 MEA
      50. | | | 4.5.5.1 GCC Countries
      51. | | | 4.5.5.2 South Africa
      52. | | | 4.5.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 Abbott Laboratories (US)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Roche Diagnostics (CH)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Siemens Healthineers (DE)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 Danaher Corporation (US)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Thermo Fisher Scientific (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Becton Dickinson and Company (US)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Cepheid (US)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Quidel Corporation (US)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 Hologic, Inc. (US)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY PRODUCT
      4. | 6.4 US MARKET ANALYSIS BY END USER
      5. | 6.5 US MARKET ANALYSIS BY MODE OF PURCHASE
      6. | 6.6 US MARKET ANALYSIS BY PLATFORM
      7. | 6.7 CANADA MARKET ANALYSIS BY PRODUCT
      8. | 6.8 CANADA MARKET ANALYSIS BY END USER
      9. | 6.9 CANADA MARKET ANALYSIS BY MODE OF PURCHASE
      10. | 6.10 CANADA MARKET ANALYSIS BY PLATFORM
      11. | 6.11 EUROPE MARKET ANALYSIS
      12. | 6.12 GERMANY MARKET ANALYSIS BY PRODUCT
      13. | 6.13 GERMANY MARKET ANALYSIS BY END USER
      14. | 6.14 GERMANY MARKET ANALYSIS BY MODE OF PURCHASE
      15. | 6.15 GERMANY MARKET ANALYSIS BY PLATFORM
      16. | 6.16 UK MARKET ANALYSIS BY PRODUCT
      17. | 6.17 UK MARKET ANALYSIS BY END USER
      18. | 6.18 UK MARKET ANALYSIS BY MODE OF PURCHASE
      19. | 6.19 UK MARKET ANALYSIS BY PLATFORM
      20. | 6.20 FRANCE MARKET ANALYSIS BY PRODUCT
      21. | 6.21 FRANCE MARKET ANALYSIS BY END USER
      22. | 6.22 FRANCE MARKET ANALYSIS BY MODE OF PURCHASE
      23. | 6.23 FRANCE MARKET ANALYSIS BY PLATFORM
      24. | 6.24 RUSSIA MARKET ANALYSIS BY PRODUCT
      25. | 6.25 RUSSIA MARKET ANALYSIS BY END USER
      26. | 6.26 RUSSIA MARKET ANALYSIS BY MODE OF PURCHASE
      27. | 6.27 RUSSIA MARKET ANALYSIS BY PLATFORM
      28. | 6.28 ITALY MARKET ANALYSIS BY PRODUCT
      29. | 6.29 ITALY MARKET ANALYSIS BY END USER
      30. | 6.30 ITALY MARKET ANALYSIS BY MODE OF PURCHASE
      31. | 6.31 ITALY MARKET ANALYSIS BY PLATFORM
      32. | 6.32 SPAIN MARKET ANALYSIS BY PRODUCT
      33. | 6.33 SPAIN MARKET ANALYSIS BY END USER
      34. | 6.34 SPAIN MARKET ANALYSIS BY MODE OF PURCHASE
      35. | 6.35 SPAIN MARKET ANALYSIS BY PLATFORM
      36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY PRODUCT
      37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY END USER
      38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY MODE OF PURCHASE
      39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY PLATFORM
      40. | 6.40 APAC MARKET ANALYSIS
      41. | 6.41 CHINA MARKET ANALYSIS BY PRODUCT
      42. | 6.42 CHINA MARKET ANALYSIS BY END USER
      43. | 6.43 CHINA MARKET ANALYSIS BY MODE OF PURCHASE
      44. | 6.44 CHINA MARKET ANALYSIS BY PLATFORM
      45. | 6.45 INDIA MARKET ANALYSIS BY PRODUCT
      46. | 6.46 INDIA MARKET ANALYSIS BY END USER
      47. | 6.47 INDIA MARKET ANALYSIS BY MODE OF PURCHASE
      48. | 6.48 INDIA MARKET ANALYSIS BY PLATFORM
      49. | 6.49 JAPAN MARKET ANALYSIS BY PRODUCT
      50. | 6.50 JAPAN MARKET ANALYSIS BY END USER
      51. | 6.51 JAPAN MARKET ANALYSIS BY MODE OF PURCHASE
      52. | 6.52 JAPAN MARKET ANALYSIS BY PLATFORM
      53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY PRODUCT
      54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY END USER
      55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY MODE OF PURCHASE
      56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY PLATFORM
      57. | 6.57 MALAYSIA MARKET ANALYSIS BY PRODUCT
      58. | 6.58 MALAYSIA MARKET ANALYSIS BY END USER
      59. | 6.59 MALAYSIA MARKET ANALYSIS BY MODE OF PURCHASE
      60. | 6.60 MALAYSIA MARKET ANALYSIS BY PLATFORM
      61. | 6.61 THAILAND MARKET ANALYSIS BY PRODUCT
      62. | 6.62 THAILAND MARKET ANALYSIS BY END USER
      63. | 6.63 THAILAND MARKET ANALYSIS BY MODE OF PURCHASE
      64. | 6.64 THAILAND MARKET ANALYSIS BY PLATFORM
      65. | 6.65 INDONESIA MARKET ANALYSIS BY PRODUCT
      66. | 6.66 INDONESIA MARKET ANALYSIS BY END USER
      67. | 6.67 INDONESIA MARKET ANALYSIS BY MODE OF PURCHASE
      68. | 6.68 INDONESIA MARKET ANALYSIS BY PLATFORM
      69. | 6.69 REST OF APAC MARKET ANALYSIS BY PRODUCT
      70. | 6.70 REST OF APAC MARKET ANALYSIS BY END USER
      71. | 6.71 REST OF APAC MARKET ANALYSIS BY MODE OF PURCHASE
      72. | 6.72 REST OF APAC MARKET ANALYSIS BY PLATFORM
      73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
      74. | 6.74 BRAZIL MARKET ANALYSIS BY PRODUCT
      75. | 6.75 BRAZIL MARKET ANALYSIS BY END USER
      76. | 6.76 BRAZIL MARKET ANALYSIS BY MODE OF PURCHASE
      77. | 6.77 BRAZIL MARKET ANALYSIS BY PLATFORM
      78. | 6.78 MEXICO MARKET ANALYSIS BY PRODUCT
      79. | 6.79 MEXICO MARKET ANALYSIS BY END USER
      80. | 6.80 MEXICO MARKET ANALYSIS BY MODE OF PURCHASE
      81. | 6.81 MEXICO MARKET ANALYSIS BY PLATFORM
      82. | 6.82 ARGENTINA MARKET ANALYSIS BY PRODUCT
      83. | 6.83 ARGENTINA MARKET ANALYSIS BY END USER
      84. | 6.84 ARGENTINA MARKET ANALYSIS BY MODE OF PURCHASE
      85. | 6.85 ARGENTINA MARKET ANALYSIS BY PLATFORM
      86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT
      87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
      88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODE OF PURCHASE
      89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PLATFORM
      90. | 6.90 MEA MARKET ANALYSIS
      91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT
      92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USER
      93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY MODE OF PURCHASE
      94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY PLATFORM
      95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT
      96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USER
      97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY MODE OF PURCHASE
      98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY PLATFORM
      99. | 6.99 REST OF MEA MARKET ANALYSIS BY PRODUCT
      100. | 6.100 REST OF MEA MARKET ANALYSIS BY END USER
      101. | 6.101 REST OF MEA MARKET ANALYSIS BY MODE OF PURCHASE
      102. | 6.102 REST OF MEA MARKET ANALYSIS BY PLATFORM
      103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
      104. | 6.104 RESEARCH PROCESS OF MRFR
      105. | 6.105 DRO ANALYSIS OF HEALTHCARE
      106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
      109. | 6.109 HEALTHCARE, BY PRODUCT, 2024 (% SHARE)
      110. | 6.110 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion)
      111. | 6.111 HEALTHCARE, BY END USER, 2024 (% SHARE)
      112. | 6.112 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
      113. | 6.113 HEALTHCARE, BY MODE OF PURCHASE, 2024 (% SHARE)
      114. | 6.114 HEALTHCARE, BY MODE OF PURCHASE, 2024 TO 2035 (USD Billion)
      115. | 6.115 HEALTHCARE, BY PLATFORM, 2024 (% SHARE)
      116. | 6.116 HEALTHCARE, BY PLATFORM, 2024 TO 2035 (USD Billion)
      117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY PRODUCT, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY END USER, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      7. | | 7.2.4 BY PLATFORM, 2025-2035 (USD Billion)
      8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      9. | | 7.3.1 BY PRODUCT, 2025-2035 (USD Billion)
      10. | | 7.3.2 BY END USER, 2025-2035 (USD Billion)
      11. | | 7.3.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      12. | | 7.3.4 BY PLATFORM, 2025-2035 (USD Billion)
      13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      14. | | 7.4.1 BY PRODUCT, 2025-2035 (USD Billion)
      15. | | 7.4.2 BY END USER, 2025-2035 (USD Billion)
      16. | | 7.4.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      17. | | 7.4.4 BY PLATFORM, 2025-2035 (USD Billion)
      18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      19. | | 7.5.1 BY PRODUCT, 2025-2035 (USD Billion)
      20. | | 7.5.2 BY END USER, 2025-2035 (USD Billion)
      21. | | 7.5.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      22. | | 7.5.4 BY PLATFORM, 2025-2035 (USD Billion)
      23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.6.1 BY PRODUCT, 2025-2035 (USD Billion)
      25. | | 7.6.2 BY END USER, 2025-2035 (USD Billion)
      26. | | 7.6.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      27. | | 7.6.4 BY PLATFORM, 2025-2035 (USD Billion)
      28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      29. | | 7.7.1 BY PRODUCT, 2025-2035 (USD Billion)
      30. | | 7.7.2 BY END USER, 2025-2035 (USD Billion)
      31. | | 7.7.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      32. | | 7.7.4 BY PLATFORM, 2025-2035 (USD Billion)
      33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      34. | | 7.8.1 BY PRODUCT, 2025-2035 (USD Billion)
      35. | | 7.8.2 BY END USER, 2025-2035 (USD Billion)
      36. | | 7.8.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      37. | | 7.8.4 BY PLATFORM, 2025-2035 (USD Billion)
      38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      39. | | 7.9.1 BY PRODUCT, 2025-2035 (USD Billion)
      40. | | 7.9.2 BY END USER, 2025-2035 (USD Billion)
      41. | | 7.9.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      42. | | 7.9.4 BY PLATFORM, 2025-2035 (USD Billion)
      43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.10.1 BY PRODUCT, 2025-2035 (USD Billion)
      45. | | 7.10.2 BY END USER, 2025-2035 (USD Billion)
      46. | | 7.10.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      47. | | 7.10.4 BY PLATFORM, 2025-2035 (USD Billion)
      48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      49. | | 7.11.1 BY PRODUCT, 2025-2035 (USD Billion)
      50. | | 7.11.2 BY END USER, 2025-2035 (USD Billion)
      51. | | 7.11.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      52. | | 7.11.4 BY PLATFORM, 2025-2035 (USD Billion)
      53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      54. | | 7.12.1 BY PRODUCT, 2025-2035 (USD Billion)
      55. | | 7.12.2 BY END USER, 2025-2035 (USD Billion)
      56. | | 7.12.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      57. | | 7.12.4 BY PLATFORM, 2025-2035 (USD Billion)
      58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      59. | | 7.13.1 BY PRODUCT, 2025-2035 (USD Billion)
      60. | | 7.13.2 BY END USER, 2025-2035 (USD Billion)
      61. | | 7.13.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      62. | | 7.13.4 BY PLATFORM, 2025-2035 (USD Billion)
      63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.14.1 BY PRODUCT, 2025-2035 (USD Billion)
      65. | | 7.14.2 BY END USER, 2025-2035 (USD Billion)
      66. | | 7.14.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      67. | | 7.14.4 BY PLATFORM, 2025-2035 (USD Billion)
      68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      69. | | 7.15.1 BY PRODUCT, 2025-2035 (USD Billion)
      70. | | 7.15.2 BY END USER, 2025-2035 (USD Billion)
      71. | | 7.15.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      72. | | 7.15.4 BY PLATFORM, 2025-2035 (USD Billion)
      73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      74. | | 7.16.1 BY PRODUCT, 2025-2035 (USD Billion)
      75. | | 7.16.2 BY END USER, 2025-2035 (USD Billion)
      76. | | 7.16.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      77. | | 7.16.4 BY PLATFORM, 2025-2035 (USD Billion)
      78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      79. | | 7.17.1 BY PRODUCT, 2025-2035 (USD Billion)
      80. | | 7.17.2 BY END USER, 2025-2035 (USD Billion)
      81. | | 7.17.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      82. | | 7.17.4 BY PLATFORM, 2025-2035 (USD Billion)
      83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.18.1 BY PRODUCT, 2025-2035 (USD Billion)
      85. | | 7.18.2 BY END USER, 2025-2035 (USD Billion)
      86. | | 7.18.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      87. | | 7.18.4 BY PLATFORM, 2025-2035 (USD Billion)
      88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      89. | | 7.19.1 BY PRODUCT, 2025-2035 (USD Billion)
      90. | | 7.19.2 BY END USER, 2025-2035 (USD Billion)
      91. | | 7.19.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      92. | | 7.19.4 BY PLATFORM, 2025-2035 (USD Billion)
      93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      94. | | 7.20.1 BY PRODUCT, 2025-2035 (USD Billion)
      95. | | 7.20.2 BY END USER, 2025-2035 (USD Billion)
      96. | | 7.20.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      97. | | 7.20.4 BY PLATFORM, 2025-2035 (USD Billion)
      98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      99. | | 7.21.1 BY PRODUCT, 2025-2035 (USD Billion)
      100. | | 7.21.2 BY END USER, 2025-2035 (USD Billion)
      101. | | 7.21.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      102. | | 7.21.4 BY PLATFORM, 2025-2035 (USD Billion)
      103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.22.1 BY PRODUCT, 2025-2035 (USD Billion)
      105. | | 7.22.2 BY END USER, 2025-2035 (USD Billion)
      106. | | 7.22.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      107. | | 7.22.4 BY PLATFORM, 2025-2035 (USD Billion)
      108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      109. | | 7.23.1 BY PRODUCT, 2025-2035 (USD Billion)
      110. | | 7.23.2 BY END USER, 2025-2035 (USD Billion)
      111. | | 7.23.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      112. | | 7.23.4 BY PLATFORM, 2025-2035 (USD Billion)
      113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      114. | | 7.24.1 BY PRODUCT, 2025-2035 (USD Billion)
      115. | | 7.24.2 BY END USER, 2025-2035 (USD Billion)
      116. | | 7.24.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      117. | | 7.24.4 BY PLATFORM, 2025-2035 (USD Billion)
      118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      119. | | 7.25.1 BY PRODUCT, 2025-2035 (USD Billion)
      120. | | 7.25.2 BY END USER, 2025-2035 (USD Billion)
      121. | | 7.25.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      122. | | 7.25.4 BY PLATFORM, 2025-2035 (USD Billion)
      123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      124. | | 7.26.1 BY PRODUCT, 2025-2035 (USD Billion)
      125. | | 7.26.2 BY END USER, 2025-2035 (USD Billion)
      126. | | 7.26.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      127. | | 7.26.4 BY PLATFORM, 2025-2035 (USD Billion)
      128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      129. | | 7.27.1 BY PRODUCT, 2025-2035 (USD Billion)
      130. | | 7.27.2 BY END USER, 2025-2035 (USD Billion)
      131. | | 7.27.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      132. | | 7.27.4 BY PLATFORM, 2025-2035 (USD Billion)
      133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      134. | | 7.28.1 BY PRODUCT, 2025-2035 (USD Billion)
      135. | | 7.28.2 BY END USER, 2025-2035 (USD Billion)
      136. | | 7.28.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      137. | | 7.28.4 BY PLATFORM, 2025-2035 (USD Billion)
      138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      139. | | 7.29.1 BY PRODUCT, 2025-2035 (USD Billion)
      140. | | 7.29.2 BY END USER, 2025-2035 (USD Billion)
      141. | | 7.29.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      142. | | 7.29.4 BY PLATFORM, 2025-2035 (USD Billion)
      143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      144. | | 7.30.1 BY PRODUCT, 2025-2035 (USD Billion)
      145. | | 7.30.2 BY END USER, 2025-2035 (USD Billion)
      146. | | 7.30.3 BY MODE OF PURCHASE, 2025-2035 (USD Billion)
      147. | | 7.30.4 BY PLATFORM, 2025-2035 (USD Billion)
      148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      149. | | 7.31.1
      150. | 7.32 ACQUISITION/PARTNERSHIP
      151. | | 7.32.1

    Point of Care Diagnostics Testing Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions